NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
- Positive results from the ALPINE 4 study: a randomized, double-blind, placebo-controlled, multicenter, Phase 2b trial evaluating multiple doses of aldafermin in patients with compensated cirrhosis due to nonalcoholic steatohepatitis
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to comprehensive results from the company’s Phase 2b ALPINE4 trial of aldafermin in patients with compensated cirrhosis (liver fibrosis stage 4, or, F4) due to nonalcoholic steatohepatitis (NASH) has been selected for an oral plenary presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, which will take place November 10-14, 2023, in Boston, MA.
Oral Presentation at AASLD The Liver Meeting
| Title: | Positive results from the ALPINE 4 study: a randomized, double-blind, placebo-controlled, multicenter, Phase 2b trial evaluating multiple doses of the FGF19 analogue aldafermin in patients with compensated cirrhosis due to nonalcoholic steatohepatitis |
| Session: | Clinical Plenary |
| Presenter: | Prof. Mary Rinella, University of Chicago Pritzker School of Medicine |
| Location: | Boston, MA |
| Date and Time: | Monday, November 13, 2023, at 9:45 AM-10:00 AM EST |
The ALPINE 4 data being shared at AASLD’s The Liver Meeting follows positive topline results reported by NGM Bio in May 2023 from the completed 48-week, randomized, double-blind, placebo-controlled, multicenter, Phase 2b trial evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin in patients with compensated cirrhosis (F4) due to NASH. The study met its primary endpoint with a statistically significant reduction in Enhanced Liver Fibrosis, or ELF, score from baseline to week 48 in patients treated with 3 mg of aldafermin versus patients receiving placebo.
For more details on NGM Bio’s liver & metabolic diseases portfolio visit NGM Bio’s website at https://www.ngmbio.com/pipeline/.
About NGM Bio
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Today, the company has four solid tumor oncology programs in clinical development. Visit us at www.ngmbio.com for more information.
| Investor Contact: ir@ngmbio.com | Media Contact: media@ngmbio.com | |
FAQ
What is the Phase 2b ALPINE4 trial?
What were the results of the trial?
When and where will the results be presented?
Where can I find more information about NGM Bio's liver and metabolic diseases portfolio?
